Phase III
Novo Nordisk’s semaglutide, an oral GLP-1 analogue, continues to rack up positive Phase III clinical trial data compared to its competitors.
The first company has provided a potential out-of-pocket price for patients who seek access through the recently passed federal Right-to-Try legislation and it’s not cheap.
Shares of Bedford, Mass.-based Anika Therapeutics have plunged more than 20 percent in premarket trading.
Array is anxiously awaiting the FDA to approve its combination treatment for BRAF-mutant metastatic melanoma. If approved, Chief Executive Officer Ron Squarer believes it will not only be an important milestone for the company, but also for the patients.
Ortho Dermatologics, a division of Quebec-based Valeant Pharmaceuticals International, received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Duobrii for plaque psoriasis.
June is Alzheimer’s & Brain Awareness Month and June 21 is dubbed “The Longest Day,” which focuses on raising awareness of Alzheimer’s disease.
Ernest Loumaye, chief executive officer of Switzerland-based ObsEva, is excited about the potential opportunity to provide women a significant treatment for endometriosis-associated pain.
Monday, June 18, the agency will make a decision on Ortho Dermatologics’ New Drug Application (NDA) for IDP-118 lotion for plaque psoriasis. On June 13th, SCPharmaceuticals received a CRL for its Furoscix infusor.
Teva has a new headache. As the company pushes forward with its cost-cutting strategies, the company reported it is scrapping its chronic cluster headache program with fremanezumab.
Shares of Motif Bio plc shot up late Thursday after the company announced it had completed its rolling submission of a New Drug Application to the U.S. Food and Drug Administration for its acute bacterial skin and skin structure infections (ABSSSI) treatment, iclaprim.
PRESS RELEASES